Showing results (211-220 of 346) with videos related to

Sort By:
Pageof 35
Haematologica|August 8, 2015
Better allele-level matching improves transplant-related mortality after double cord blood transplantationBetül Oran, Kai Cao, Rima M Saliba, et al.
Transplantation and Cellular Therapy|September 6, 2023
Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple MyelomaOren Pasvolsky, Sassine Ghanem, Denái R Milton, et al.
Cancer|December 21, 2023
Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantationOren Pasvolsky, Sarah Pasyar, Roland L Bassett, et al.
Haematologica|November 30, 2023
Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapyAndrew P Jallouk, Naishu Kui, Ryan Sun, et al.
Cancer|June 17, 2021
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysisKoji Sasaki, Hagop M Kantarjian, Kiyomi Morita, et al.
Bone Marrow Transplantation|April 14, 2015
Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantationMarina Konopleva, Christopher B Benton, Peter F Thall, et al.
Blood|July 25, 2022
The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysisArmin Ghobadi, Michael Slade, Hagop Kantarjian, et al.
Blood Advances|October 20, 2017
US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALLFarhad Ravandi, Megan Othus, Susan M O'Brien, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 5, 2018
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin LymphomaYago Nieto, Peter F Thall, Junsheng Ma, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 22, 2020
Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical TrialUday Popat, Rohtesh S Mehta, Roland Bassett, et al.
Pageof 35